D'Antonio Gianpiero, Di Fazio Nicola, Pellegrini Lavinia, Ghamlouch Alessandro, Del Duca Fabio, La Russa Raffaele, Frati Paola, Maiese Aniello, Volonnino Gianpietro
Department of Anatomical, Histological, Forensic and Orthopedic Sciences, Sapienza University of Rome, Viale Regina Elena 336, 00161 Rome, Italy.
Department of Life Sciences, Health and Health Professions, Link Campus University, 00165 Rome, Italy.
Int J Mol Sci. 2025 Sep 12;26(18):8901. doi: 10.3390/ijms26188901.
In forensic medicine, spotting signs of an acute myocardial infarction (AMI) right after it happens is still a tough call, especially in sudden-death cases. Standard histology often misses changes in those critical first hours because the tissue damage is too subtle to see. To tackle this, we reviewed research (1990-2023) from PubMed and Web of Science, following PRISMA guidelines. We focused on studies that used immunohistochemistry to identify markers of early AMI in both human autopsies and animal models, specifically in the first six hours post-event. Our selection process narrowed 418 records to 37 key papers. We screened 49 markers in total, but only a handful stood out for reliable diagnosis: C5b-9, cardiac troponins, dystrophin, and H-FABP-all showing high specificity. Markers like S100A1 and IL-15 also showed promise, whereas JunB and connexin-43 appeared less dependable. We believe immunohistochemistry can add real value in early AMI identification, especially when using combinations of markers chosen for complementary strengths. Still, to make this approach practical in forensic settings, we need more studies on human samples and agreement on standardized lab protocols.
在法医学中,在急性心肌梗死(AMI)发生后立即发现其迹象仍然是一项艰巨的任务,尤其是在猝死病例中。标准组织学常常会忽略最初几个关键小时内的变化,因为组织损伤过于细微而难以察觉。为了解决这个问题,我们按照PRISMA指南,回顾了来自PubMed和科学网(1990 - 2023年)的研究。我们重点关注了那些在人体尸检和动物模型中,特别是在事件发生后的头六个小时内,使用免疫组织化学来识别早期AMI标志物的研究。我们的筛选过程将418条记录缩小到37篇关键论文。我们总共筛选了49种标志物,但只有少数几种在可靠诊断方面表现突出:C5b - 9、心肌肌钙蛋白、肌营养不良蛋白和H - FABP,所有这些都显示出高特异性。像S100A1和IL - 15这样的标志物也显示出前景,而JunB和连接蛋白 - 43似乎不太可靠。我们相信免疫组织化学在早期AMI识别中可以增加实际价值,特别是当使用为互补优势而选择的标志物组合时。然而,为了使这种方法在法医环境中切实可行,我们需要对人体样本进行更多研究,并就标准化实验室方案达成一致。